Posted in
Notícias -
Institucional
The proposal, which is on public consultation, should be published today
FROM BRASÍLIA
Anvisa (National Health Surveillance Agency) promises to simplify and make the approval to carry out clinical researches aimed at the development of drugs and health products faster.
The clinical research is one of the last steps before the registration of new products and involves tests with patients.
The idea is that researches which have already been approved by recognized agencies abroad – such as the American (FDA), the Australian and the Japanese – may go through a simplified analysis procedure by Anvisa.
And this proposal was approved by the Collegiate Board of the Agency on the day before yesterday and should be published today in the form of a public consultation, open for the next 30 days.
INTERNATIONAL
The direct impact will be greater in researches originated in a foreign country and with arms in many others, one of which Brazil, according to Dirceu Barbano, CEO of the Health Surveillance Agency.
"Our standard was to analyze the whole study [carried out abroad] again. It takes time; it sometimes meant that Brazil would be excluded from the study. We came to the conclusion that a simplified analysis is possible, evaluating specific health risk issues in the country,” he says.
Issues such as which centers will be used and if they have the capacity to develop the study will be evaluated by Anvisa, but the study design (such as the statistical calculation to ensure the effectiveness of the analysis), will not.
DELAY
According to Barbano, the wait for the authorization of such researches has already been three months, but due to the increase in demand for national research centers, the delay may be up to seven months today. The goal is that this time drops to 30 days.
As a result, the agency would still have more agility in the approval of fully national researches, which need to go through a comprehensive analysis of Anvisa.
Greyce Lousana, Executive President of SSPPC (Brazilian Society of Clinical Research Professionals), says that the reduction in the time limits could open the way for patients with serious or rare diseases to have access to experimental drugs.
She says that, recently, a research on breast cancer did not come to Brazil due to lengthy time limits – from Anvisa and the Ethics Committee of the institution - and therefore failed to benefit about one hundred patients.
Lousana, however, supports further changes to the regulation in force, such as totally separate analyses between drugs and other health products, which can shorten the time limits for analysis. (JN)
The proposal, which is on public consultation, should be published today
FROM BRASÍLIA
Anvisa (National Health Surveillance Agency) promises to simplify and make the approval to carry out clinical researches aimed at the development of drugs and health products faster.The clinical research is one of the last steps before the registration of new products and involves tests with patients.
The idea is that researches which have already been approved by recognized agencies abroad – such as the American (FDA), the Australian and the Japanese – may go through a simplified analysis procedure by Anvisa.
And this proposal was approved by the Collegiate Board of the Agency on the day before yesterday and should be published today in the form of a public consultation, open for the next 30 days.
INTERNATIONAL
The direct impact will be greater in researches originated in a foreign country and with arms in many others, one of which Brazil, according to Dirceu Barbano, CEO of the Health Surveillance Agency.
"Our standard was to analyze the whole study [carried out abroad] again. It takes time; it sometimes meant that Brazil would be excluded from the study. We came to the conclusion that a simplified analysis is possible, evaluating specific health risk issues in the country,” he says.
Issues such as which centers will be used and if they have the capacity to develop the study will be evaluated by Anvisa, but the study design (such as the statistical calculation to ensure the effectiveness of the analysis), will not.
DELAY
According to Barbano, the wait for the authorization of such researches has already been three months, but due to the increase in demand for national research centers, the delay may be up to seven months today. The goal is that this time drops to 30 days.
As a result, the agency would still have more agility in the approval of fully national researches, which need to go through a comprehensive analysis of Anvisa.
Greyce Lousana, Executive President of SSPPC (Brazilian Society of Clinical Research Professionals), says that the reduction in the time limits could open the way for patients with serious or rare diseases to have access to experimental drugs.She says that, recently, a research on breast cancer did not come to Brazil due to lengthy time limits – from Anvisa and the Ethics Committee of the institution - and therefore failed to benefit about one hundred patients.
Lousana, however, supports further changes to the regulation in force, such as totally separate analyses between drugs and other health products, which can shorten the time limits for analysis. (JN)
English
Arabic
Bulgarian
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hindi
Italian
Japanese
Korean
Norwegian
Polish
Portuguese
Romanian
Russian
Spanish
Swedish
Catalan
Filipino
Hebrew
Indonesian
Latvian
Lithuanian
Serbian
Slovak
Slovenian
Ukrainian
Vietnamese
Albanian
Estonian
Galician
Hungarian
Maltese
Thai
Turkish
Persian
Afrikaans
Malay
Swahili
Irish
Welsh
Belarusian
Icelandic
Macedonian
Yiddish
Armenian
Azerbaijani
Basque
Georgian
Haitian Creole
Urdu
Chinese (S)
Chinese (T)
Consulta Pública No. 30